NTRA
Natera, Inc. · Healthcare
207.98
2.35%(+4.77)
Market Closed212.20
2.03%(+4.22)
After HoursLast Updated: — ET
52W L: $125.3852W H: $256.36
$208.40
CHG+11.26 (+5.71%)
H$210.99
L$181.01
VOL21M
NTRA (1h)
Natera, Inc. · Healthcare
Exchange Traded Concepts LLC lessened its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 40.4% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 4,346 shares of the medical research company's stock after selling 2,945 shares during the period. Exchange Traded Concepts LLC's holdings in
Natera stock is showing exceptional strength. What's fueling NTRA momentum?
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a publication in Clinical Cancer Research showing that Signatera was able to identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy (pET), without surgery. While pET can be an alternative to surgery for patients with early breast cancer, tools for risk stratification and monitoring have been limited. This p.
Connective Portfolio Management LLC bought a new stake in shares of Natera, Inc. (NASDAQ: NTRA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,400 shares of the medical research company's stock, valued at approximately $779,000.
NTRA's oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in cancer monitoring and recurrence detection. NTRA's 2025 also included new product launches and added Medicare coverage, advanced early cancer detection, and broadened its molecular diagnostics portfolio.
Bamco Inc. NY lessened its stake in Natera, Inc. (NASDAQ: NTRA) by 53.3% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,500 shares of the medical research company's stock after selling 4,000 shares during the quarter. Bamco Inc. NY's
RABINOWITZ DANIEL
officer: SEC. AND CHIEF LEGAL OFFICER
300 SH @ $200.79
2026-04-01
RABINOWITZ DANIEL
officer: SEC. AND CHIEF LEGAL OFFICER
1,778 SH @ $202.01
2026-04-01
RABINOWITZ DANIEL
officer: SEC. AND CHIEF LEGAL OFFICER
3,213 SH @ $203.07
2026-04-01
RABINOWITZ DANIEL
officer: SEC. AND CHIEF LEGAL OFFICER
1,200 SH @ $203.83
2026-04-01
RABINOWITZ DANIEL
officer: SEC. AND CHIEF LEGAL OFFICER
1,909 SH @ $205.00
2026-04-01
Moshkevich Solomon
officer: PRESIDENT, CLINICALDIAGNOSTICS
1,048 SH @ $201.32
2026-04-01
Moshkevich Solomon
officer: PRESIDENT, CLINICALDIAGNOSTICS
1,000 SH @ $202.36
2026-04-01
Moshkevich Solomon
officer: PRESIDENT, CLINICALDIAGNOSTICS
952 SH @ $203.31
2026-04-01